Elsevier

The Lancet

Volume 341, Issue 8837, 9 January 1993, Pages 85-86
The Lancet

SHORT REPORTS
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation

https://doi.org/10.1016/0140-6736(93)92560-GGet rights and content

Abstract

Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.

Cited by (893)

  • Starch magnetic nanocomposites for gene delivery

    2021, Polysaccharide-Based Nanocomposites for Gene Delivery and Tissue Engineering
  • Practical Aspects of Hematologic Stem Cell Harvesting and Mobilization

    2018, Hematology: Basic Principles and Practice
  • Practical Aspects of Hematologic Stem Cell Harvesting and Mobilization

    2017, Hematology: Basic Principles and Practice
  • Utilization of chitosan for gene delivery

    2023, Integration of Biomaterials for Gene Therapy
View all citing articles on Scopus
View full text